Table 2.
Associations between baseline plasma lnMMP-1, -2, -3, -9 and -10 and lnTIMP-1 and incident cardiovascular disease (n = 86)
| Model | MMP-1 | MMP-2 | MMP-3 | MMP-9 | MMP-10 | TIMP-1 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | |
| 1 | 1.51 | 1.20; 1.91 | <0.001 | 1.65 | 1.28; 2.13 | <0.001 | 1.47 | 1.13; 1.92 | 0.004 | 1.44 | 1.17; 1.78 | 0.001 | 1.20 | 0.97; 1.50 | 0.101 | 1.87 | 1.40; 2.49 | <0.001 |
| 2 | 1.26 | 1.00; 1.60 | 0.054 | 1.49 | 1.11; 1.99 | 0.007 | 1.16 | 0.88; 1.53 | 0.308 | 1.24 | 0.99; 1.55 | 0.058 | 1.03 | 0.82; 1.29 | 0.801 | 1.33 | 0.95; 1.87 | 0.100 |
| 3 | 1.23 | 0.96; 1.59 | 0.103 | 1.34 | 0.96; 1.85 | 0.085 | 0.99 | 0.73; 1.34 | 0.991 | 1.21 | 0.96; 1.52 | 0.112 | 0.91 | 0.71; 1.16 | 0.440 | 1.03 | 0.72; 1.49 | 0.858 |
| 4 | 1.23 | 0.97; 1.55 | 0.094 | 1.47 | 1.11; 1.96 | 0.008 | 1.15 | 0.87; 1.52 | 0.321 | 1.18 | 0.93; 1.48 | 0.173 | 1.02 | 0.81; 1.28 | 0.890 | 1.23 | 0.87; 1.75 | 0.243 |
| 5 | 1.28 | 1.01; 1.63 | 0.043 | 1.48 | 1.11; 1.98 | 0.008 | 1.16 | 0.88; 1.54 | 0.284 | 1.24 | 1.00; 1.55 | 0.055 | 1.03 | 0.82; 1.29 | 0.799 | 1.32 | 0.94; 1.87 | 0.111 |
HR, hazard ratio for incident cardiovascular disease per 1 SD increase in lnMMP-1, -2, -3, -9 or -10 or lnTIMP-1, MMP matrix metalloproteinase, TIMP-1 tissue inhibitor of metalloproteinase-1
Model 1 adjusted for age, sex, HbA1c, nephropathy-no nephropathy status and duration of diabetes
Model 2 Model 1 + MAP, BMI, smoking status, total cholesterol, use of antihypertensive agents and continuation of medication use at baseline
Model 3 Model 2 + eGFR and Ln-UAE
Model 4 Model 2 + inflammatory z-score
Model 5 Model 2 + endothelial dysfunction z-score